Evaluating markers and imaging for predicting outcomes in pituitary tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify serum and tissue molecular markers, as well as imaging features, that can predict the invasiveness and prognosis of pituitary neuroendocrine tumors. Given the variability in clinical manifestations and the resistance of some tumors to conventional treatments, the study will monitor changes in these biomarkers and imaging characteristics throughout the disease course and treatment. By doing so, it seeks to improve early prediction of tumor proliferation, progression, and recurrence risk following medical or surgical interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection.

Exclusion Criteria:

1. Previous pathological specimen suggested pituitary carcinoma.
2. always have received radiation and chemotherapy or immune and targeted therapy of the patients.
3. with known genetic syndrome can cause excessive secretion of hormones (such as Carney syndrome, McCune - Albright syndrome, multiple endocrine neoplasia type 1, acute interstitial pneumonia) patients.
4. there are ectopic neuroendocrine tumor patients.
5. within one month before the screening for major surgery, or within 3 months before screening for patients with sphenoid pituitary surgery.
6. crisis of gland function (the pituitary gland, thyroid crisis, adrenal crisis).
7. peripheral glands or other solid tumors in patients with severe disease or blood system.
8. serious organ damage such as heart, kidney, liver, etc.
9. with severe mental or nervous system disease.
10. serious high blood glucose or poorly controlled hypertension or emergency patients.

Where it's running

• endocrinology department of the first affiliated hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New DLL3 PET/CT imaging for neuroendocrine tumors compared with standard scans

  A new PET/CT scan using the 68Ga-DLL3 nanobody is being tested to see if it detects metastatic neuroendocrine tumors better than current scans in adults.

  Recruiting at 2 sites Phase 2 Peking University First Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07733024

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Fluid-based PET imaging to locate ACTH-secreting pituitary adenomas in Cushing disease

  This study tests whether FET PET/CT scanning can accurately locate ACTH-secreting pituitary adenomas in adults with Cushing disease who are planning pituitary surgery.

  Recruiting Early Phase 1 Mayo Clinic · Rochester, Minnesota · NCT07460232

• FET-PET/MRI to locate small hormone-producing pituitary adenomas

  This trial tests whether a special PET/MRI scan called FET-PET/MRI can find small hormone-producing pituitary adenomas in adults whose standard MRI is negative or unclear.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT07456878

• Terbium-161 DOTATATE for metastatic gastro‑enteropancreatic neuroendocrine tumors

  This trial tests terbium-161 DOTATATE, a targeted radioactive drug, in adults with metastatic well-differentiated GEP‑NETs who have progressed after lutetium‑177 therapy.

  Recruiting at 2 sites Phase 2 Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07404176

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.